Regeneron's Future May Depend on Dupixent Amid Eylea Sales Decline
Regeneron Pharmaceuticals has underperformed broader equities in recent years due to declining sales of its drug Eylea, which treats eye-related conditions. Despite launching a newer formulation (Eylea HD), combined U.S. revenue from both versions dropped by 12% year over year. However, the company's collaboration with Sanofi on Dupixent has been a major growth driver. In Q2, global sales of Dupixent reached $6 billion, up 38%, and Regeneron’s overall revenue grew 17% to $4.3 billion. Dupixent is approved for multiple conditions including eczema, asthma, and COPD, with Sanofi handling global sales while profits are shared between the two companies. The drug's strong performance helped offset Eylea-related challenges, contributing significantly to Regeneron’s 11% year-over-year increase in non-GAAP net income per share. Looking ahead, Dupixent is expected to reach peak revenue of $27.8 billion by 2030 before facing biosimilar competition. Regeneron and Sanofi are preparing for this with new formulations and pipeline candidates.
Topics: Drug Sales Dupixent Eylea Pharmaceuticals Regeneron Pharmaceuticals